阐明一个元型谷氨酸受体异构聚合物的分子逻辑
Xin Lin1,2, Davide Provasi3, Colleen M Niswender4,5,6,7,8
1Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Nature communications
|October 3, 2024
概括
甲基氨酸 (mGlu) 受体异构体表现出不同的药理学. 这项研究揭示了mGlu2/4异构体与同构体的信号如何不同,这对神经精神疾病治疗有意义.
科学领域:
- 神经科学是一个神经科学.
- 分子药理学分子药理学
- 生物化学 生物化学
背景情况:
- 甲基增生谷氨酸 (mGlu) 受体原体可以形成异构体,改变它们的药理特性与同构体相比.
- 了解mGlu异构体的特定信号机制对于开发向疗法至关重要.
研究的目的:
- 阐明mGlu2/4异构体的激活机制和差异性药理学.
- 为了研究质调节器结合部位在异构体功能中的作用.
主要方法:
- 补充的捐赠者-接受器共振能量传输 (CODA-RET) 技术,以区分同极体和异极体信号.
- 受体原体的有针对性的突变发生.
- 计算对接研究.
主要成果:
- 针对mGlu4上方全囊的阳性全调节剂 (PAMs) 在mGlu4/4同质体和mGlu2/4异质体中都活跃.
- 针对下方全囊的PAMs在同质体中是活跃的,但不是异质体.
- mGlu2/4异构体表现出不对称的信号,mGlu4 PAMs促进转激活到mGlu2并增强mGlu2的cis激活,而mGlu2 PAMs主要增强mGlu2的cis激活.
结论:
- 这项研究提供了对调控mGlu2/4异构体激活和信号传递的分子逻辑的见解.
- 根据结合口袋的位置证明了全调节剂的差异性药理学.
- 这些发现对于推进神经精神疾病的精确向疗法至关重要.
相关概念视频
Cooperative Allosteric Transitions
7.9K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
7.9K
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.2K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.2K
The Two-State Receptor Model
1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.9K
Activation and Inactivation of G Proteins
6.8K
Heterotrimeric G proteins are guanine nucleotide-binding proteins. As the name suggests, heterotrimeric G proteins are composed of three subunits: alpha, beta, and gamma. They remain GDP-bound or GTP-bound inside the cells and switch between inactive/active states. The Gα subunit possesses the nucleotide-binding pocket that binds guanine nucleotides and switches between GDP or GTP-bound states. In contrast, the Gꞵ and Gγ subunits are always bound together with high...
6.8K
Ligand-gated Ion Channels
12.3K
Ligand-gated ion channels are transmembrane proteins with a channel for ions to pass through and a binding site for a ligand. The channel opens only when a ligand attaches to the binding site.
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
12.3K
Transducer Mechanism: G Protein–Coupled Receptors
1.9K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
1.9K


